Oxford BioDynamics – a spin out company from the University of Oxford – has appointed Martin Reeves as its new senior vice president, commercial development.
His career to date has seen him hold positions such as head of business development, global branded products at Teva Pharmaceuticals, VP of business development and strategic planning at Cephalon and various project management roles at Wyeth-Ayerst and SmithKline Beecham.
Christian Hoyer Millar, CEO at Oxford BioDynamics, said: “His considerable experience in business development within the sector will be a great asset to Oxford BioDynamics as we look to leverage IP licensing opportunities with our award-winning, proprietary technology platform EpiSwitch.”